VanEck Associates’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$216M Sell
1,792,705
-2,071,624
-54% -$239M 0.16% 113
2025
Q4
$407M Sell
3,864,329
-1,460,704
-27% -$137M 0.34% 56
2025
Q3
$447M Buy
5,325,033
+2,029,342
+62% +$167M 0.42% 51
2025
Q2
$261M Buy
3,295,691
+203,845
+7% +$16.2M 0.3% 77
2025
Q1
$278M Sell
3,091,846
-57,995
-2% -$5.41M 0.36% 72
2024
Q4
$313M Buy
3,149,841
+2,778,388
+748% +$286M 0.4% 60
2024
Q3
$39.5M Buy
371,453
+49,891
+16% +$5.93M 0.05% 198
2024
Q2
$39.8M Buy
321,562
+13,148
+4% +$1.69M 0.06% 188
2024
Q1
$40.7M Buy
308,414
+75,291
+32% +$9.28M 0.06% 181
2023
Q4
$25.4M Sell
233,123
-406,270
-64% -$42.2M 0.05% 208
2023
Q3
$65.8M Buy
639,393
+34,220
+6% +$3.69M 0.14% 131
2023
Q2
$69.8M Buy
605,173
+17,821
+3% +$2.02M 0.15% 130
2023
Q1
$62.5M Sell
587,352
-138,519
-19% -$15M 0.14% 132
2022
Q4
$80.5M Sell
725,871
-122,403
-14% -$12.5M 0.21% 119
2022
Q3
$73.1M Sell
848,274
-1,177,605
-58% -$105M 0.22% 116
2022
Q2
$185M Sell
2,025,879
-995,014
-33% -$88.2M 0.49% 48
2022
Q1
$248M Sell
3,020,893
-107,916
-3% -$8.51M 0.51% 43
2021
Q4
$240M Buy
3,128,809
+161,776
+5% +$12.9M 0.55% 44
2021
Q3
$223M Buy
2,967,033
+343,962
+13% +$26.2M 0.56% 39
2021
Q2
$204M Buy
2,623,071
+408,110
+18% +$30.4M 0.48% 45
2021
Q1
$163M Buy
2,214,961
+482,194
+28% +$35.6M 0.44% 49
2020
Q4
$135M Buy
1,732,767
+179,166
+12% +$13.7M 0.39% 51
2020
Q3
$123M Buy
1,553,601
+56,553
+4% +$4.43M 0.39% 47
2020
Q2
$110M Buy
1,497,048
+201,575
+16% +$15.2M 0.38% 42
2020
Q1
$95.1M Sell
1,295,473
-32,705
-2% -$2.57M 0.48% 36
2019
Q4
$115M Buy
1,328,178
+734,720
+124% +$60.3M 0.45% 37
2019
Q3
$47.7M Buy
593,458
+419,779
+242% +$33.6M 0.22% 97
2019
Q2
$13.9M Sell
173,679
-7,259
-4% -$556K 0.07% 196
2019
Q1
$14.4M Sell
180,938
-81,168
-31% -$6.07M 0.07% 192
2018
Q4
$19.1M Sell
262,106
-349,737
-57% -$24.7M 0.1% 168
2018
Q3
$41.4M Sell
611,843
-357,050
-37% -$22.7M 0.2% 118
2018
Q2
$56.1M Buy
968,893
+55,197
+6% +$3.11M 0.26% 88
2018
Q1
$47.5M Buy
913,696
+73,038
+9% +$3.94M 0.24% 94
2017
Q4
$45.1M Buy
840,658
+350,908
+72% +$19.5M 0.22% 103
2017
Q3
$29.9M Buy
489,750
+265,373
+118% +$16.1M 0.15% 146
2017
Q2
$13.7M Sell
224,377
-40,624
-15% -$2.47M 0.08% 202
2017
Q1
$16.1M Buy
265,001
+30,865
+13% +$1.87M 0.07% 183
2016
Q4
$13.2M Buy
234,136
+34,700
+17% +$2.03M 0.07% 184
2016
Q3
$11.9M Sell
199,436
-40,755
-17% -$2.38M 0.06% 187
2016
Q2
$13.2M Sell
240,191
-19,155
-7% -$1.02M 0.07% 176
2016
Q1
$13.1M Sell
259,346
-100,382
-28% -$4.92M 0.09% 148
2015
Q4
$18.1M Sell
359,728
-739,191
-67% -$37.3M 0.14% 144
2015
Q3
$51.8M Sell
1,098,919
-2,826
-0.3% -$150K 0.4% 64
2015
Q2
$59.9M Sell
1,101,745
-40,995
-4% -$2.3M 0.35% 76
2015
Q1
$62.7M Buy
1,142,740
+856,829
+300% +$48.5M 0.36% 75
2014
Q4
$15.5M Sell
285,911
-129,081
-31% -$7.19M 0.1% 163
2014
Q3
$23.5M Buy
414,992
+58,150
+16% +$3.27M 0.12% 133
2014
Q2
$19.7M Buy
356,842
+53,477
+18% +$2.92M 0.09% 146
2014
Q1
$16.4M Buy
303,365
+17,721
+6% +$918K 0.08% 151
2013
Q4
$13.6M Buy
285,644
+5,914
+2% +$270K 0.07% 159
2013
Q3
$12.7M Sell
279,730
-63,671
-19% -$2.91M 0.06% 155
2013
Q2
$15.2M Buy
+343,401
New +$15.3M 0.08% 119

Other funds holding MRK

VanEck Associates's MRK Position: Q1 2026 in Review

VanEck Associates reduced its Merck (MRK) stake by 54% in Q1 2026, selling an estimated $239M and leaving 1,792,705 shares worth $216M. The position accounts for 0.16% of the portfolio, ranked #113.

VanEck Associates first reported a position in MRK in Q2 2013 and has held it in 52 quarters since. The position peaked at $447M in Q3 2025. 3,775 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • VanEck Associates held 1,792,705 shares of Merck worth $216M as of Q1 2026.
  • VanEck Associates sold 2,071,624 Merck shares in Q1 2026, an estimated $239M.
  • Merck made up 0.16% of VanEck Associates's portfolio in Q1 2026, its #113 holding.
  • VanEck Associates first reported a position in Merck in Q2 2013 and has held it in 52 quarters since.
  • VanEck Associates's Merck position peaked at $447M in Q3 2025.
  • 3,775 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.